Fox Business - The Power to Prosper
Search Site

Watson Pharmaceuticals

Related Topics

  1. King Pharmaceuticals
  2. Novartis
  3. Mylan
  4. Pharmaceuticals
  5. Vertex Pharmaceuticals
  6. Amylin Pharmaceuticals
Get updates on Watson Pharmaceuticals
Actavis to Buy Warner Chilcott for $5 Billion in Stock

Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specialty pharmaceutical brands--and shrinking its tax burden.The deal follows reports that Actavis itself was targeted for a takeover by potential bidders including Valeant Pharmaceuticals Inc. (VRX) and Mylan Inc. (MYL). If the Actavis-Warner Chilcott deal is completed, Actavis's lower tax rate could help it better compete with Valeant and others in search of further deals as the generic-drug and specialty-pharmaceutical sectors undergo consolidation.Companies selling niche pharmaceutical brands and low-cost generics are seeking to beef up through mergers and acquisitions to grapple with pricing pressure in developed markets including the U.S. and western Europe, and to capitalize on opportunities for stronger sales growth in emerging markets including Russia and China. Also, a wave of patent expirations for big-selling branded...

Read More ›

  1. Actavis CEO on Reducing Health-Care Costs with Biosimilar Drugs

    Actavis CEO Paul Bisaro on the latest trends in pharmaceuticals and the impact of the health-care law.

  2. Concerns Rise Ahead of Amgen's Business Update Thursday

    Amgen Inc. (AMGN) is the world's largest biotechnology company, but it is beginning to face Big Pharma-type problems that include looming patent expirations for seve...

  3. Pfizer Wins Rapamune Patent Suit Against Actavis

    Pfizer Inc. (PFE) said it won its patent infringement suit against Actavis Inc. (ACT) in a federal court in Delaware, which now prevents Actavis from marketing its g...

  4. Actavis forecasts 2012 sales in excess of 2 billion euros

    Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than 2 billion euros ($2.6 billion) this year, drive...

  5. FTC Clears Watson-Actavis Deal, With Conditions

    The Federal Trade Commission on Monday cleared Watson Pharmaceuticals Inc.'s (WPI) proposed $5.9 billion acquisition of Swiss rival Actavis, but required the compani...

  6. U.S. High Court Rejects Allergan Patent Appeal

    The U.S. Supreme Court on Monday rejected Allergan Inc's appeal of a ruling that favored generic drugmaker Watson Pharmaceuticals Inc over patents related to the tre...

  7. FDA Withdrawing Approval of 1 Impax/Teva Generic Wellbutrin Product

    One version of generic Wellbutrin comes off U.S. market-FDA tests show generic not as effective as brand name-FDA asking other drug makers to conduct additional test...

  8. U.S. finds no wrongdoing in Yasmin patent settlement

    U.S. antitrust regulators found no wrongdoing in a deal made four years ago between German drugmaker Bayer AG and a division of Teva Pharmaceuticals to end patent li...

  9. Jumbo Deals Push Monthly Corporate Bond Volume to $115 Billion

    Two jumbo-size bond deals are bringing some life back to the corporate-debt market after a couple of quiet sessions.Watson Pharmaceuticals Inc. (WPI) has a prescript...

  10. Health Care Sector Wrap

    The Health Care sector (XLV) showed little change during trading today while the S&P 500 rose 0.6%.The ETF, as a proxy for the sector, tracked closer to the overall ...

  11. Eli Lilly &, Limited Brands Included in Stocks Up on High Volume Friday

    A few stocks are up on high volume today:Eli Lilly & (NYSE:LLY) is seeing its price rise on above-normal volume today, as 29.7 million shares, six times the stock's ...

  12. Kraft Foods, Sherwin-Williams, Other Stocks Hit 52-Week Highs Friday

    These are the nine most popular stocks that rose to 52-week highs:While trading on below-average volume, Kraft Foods (NASDAQ:KFT) improved today, reaching and then s...

  1. Actavis to Buy Warner Chilcott For $5 Billion in Stock

    Drug maker Actavis Inc. (ACT) agreed to acquire Warner Chilcott PLC (WCRX) for about $5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specia...

  2. Drugmaker Actavis in Talks to Buy Warner Chilcott

    Generic drugmaker Actavis Inc, formerly Watson Pharmaceuticals, said on Friday that it was in early stage discussions to buy specialty pharmaceutical company Warner ...

  3. Actavis Swings to 1st-Quarter Loss on Charges; Raises Year View

    Actavis Inc. (ACT) swung to a first-quarter loss as acquisition, licensing and other charges masked the drug maker's revenue growth, while adjusted earnings topped c...

  4. Actavis Temporarily Enjoined From Selling Generic of AstraZeneca's Pulmicort Respules

    Actavis Inc. (ACT) confirmed a New Jersey court has granted a motion from AstraZeneca PLC (AZN) seeking a temporary restraining order to prevent Actavis from further...

  5. Supreme Court Concerned About Drug Patent Settlements

    Several members of the Supreme Court expressed concern Monday about patent settlements in which brand-name pharmaceutical companies pay generic-drug makers to drop p...

  6. AstraZeneca Settles Suit, Protecting Crestor

    AstraZeneca PLC (AZN) Monday said it had settled a long-running patent lawsuit with three generic drug makers, in a move which will help safeguard revenue from top-s...

  7. Top Court to Decide on Deals to Delay Cheaper Drugs

    The U.S. Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper...

‹ Prev123Next ›
Freebase CC-BY
Source: Watson Pharmaceuticals on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL